Research Topics
| Jack J ChenSummaryAffiliation: Loma Linda University Country: USA Publications
|
Detail Information
Publications
Essential tremor: diagnosis and treatmentJack J Chen
Department of Pharmacy Practice, College of Pharmacy, Western University of Health Sciences, Pomona, California 91766 1854, USA
Pharmacotherapy 23:1105-22. 2003..A treatment algorithm is provided to guide clinicians in the management of patients with essential tremor...
Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's diseaseJack J Chen
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
Pharmacotherapy 29:1452-67. 2009....- Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primerJack J Chen
School of Pharmacy, Shryock Hall 225, Loma Linda University, Loma Linda, CA 92350, USA
Pharmacotherapy 33:304-18. 2013.... - Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literatureJack J Chen
Movement Disorders Clinic, Schools of Medicine and Pharmacy, Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
Clin Ther 34:1487-504. 2012..This review focuses on the use of TBZ in various hyperkinetic movement disorders, which are considered "rare" or "orphan" diseases, to help practitioners better understand its clinical role and use... - The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?Jack J Chen
Department of Neurology, School of Medicine and Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, CA, USA
J Clin Pharmacol 52:620-8. 2012.... - Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate careJack J Chen
Department of Pharmacotherapy and Outcomes Science, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda, CA, USA
Am J Manag Care 17:S322-7. 2011..In addition to evaluation of symptomatic therapies for PD, attention to advances in disease-modifying therapies and to management of nonmotor symptoms should be an integral component of PD surveillance in the managed care environment... - Pharmacologic safety concerns in Parkinson's disease: facts and insightsJack J Chen
Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA
Int J Neurosci 121:45-52. 2011..Concerns about ST or hypertensive crisis should not preclude or restrict clinicians from using MAO-B inhibitors in patients with PD... - Parkinson's disease: health-related quality of life, economic cost, and implications of early treatmentJack J Chen
Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
Am J Manag Care 16:S87-93. 2010..None has demonstrated irrefutable and enduring disease-modifying qualities, although the best available clinical evidence appears most promising for rasagiline... - Pharmacotherapy for Parkinson's diseaseJack J Chen
Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA
Pharmacotherapy 27:161S-173S. 2007..Surgery may be considered when patients need additional symptomatic control or are experiencing severe motor complications despite pharmacologically optimized therapy... - Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's diseaseJack J Chen
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
Clin Ther 29:1825-49. 2007..Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)... - Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitorsJack J Chen
Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
Drugs Aging 24:663-80. 2007..The favourable safety profile of rasagiline in the elderly and its once-daily formulation may maximise drug adherence and improve outcomes... - A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's diseaseJack J Chen
Movement Disorders Center and School of Pharmacy, Loma Linda University, 1162 Campus Street West Hall, Loma Linda, CA 92350, USA
Clin Ther 27:1710-24. 2005.... - Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's diseaseJack J Chen
School of Pharmacy, Loma Linda University, 11262 Campus Street, Loma Linda, CA 92350, USA
Am J Health Syst Pharm 63:915-28. 2006..The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed... - Nonparkinsonism movement disorders in the elderlyJack J Chen
School of Pharmacy, Loma Linda University, California 92350, USA
Consult Pharm 21:58-71. 2006..The primary objective of this article is to review the clinical presentation and pharmacologic management of essential tremor and tardive dyskinesia... - Monoamine oxidase-B inhibition in the treatment of Parkinson's diseaseHubert H Fernandez
Movement Disorders Center, University of Florida, McKnight Brain Institute, Gainesville, FL 32610, USA
Pharmacotherapy 27:174S-185S. 2007..A third agent with MAO-B inhibition properties, safinamide, is in phase III development. Although not yet approved, safinamide may offer the added advantage of combined MAO-B and dopamine reuptake inhibition... - Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson diseaseJack J Chen
Movement Disorders Center, Loma Linda University, Loma Linda, CA, USA
J Clin Pharmacol 45:878-94. 2005..Thus, in addition to symptomatic benefits, rasagiline offers the promise of clinically relevant neuroprotection... - Monamine oxidase inhibitors: current and emerging agents for Parkinson diseaseHubert H Fernandez
Movement Disorders Center, Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, FL 32610, USA
Clin Neuropharmacol 30:150-68. 2007..Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects... - Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's diseaseCrystal D Obering
School of Pharmacy, University of Missouri Kansas City, and the Department of Pharmacy, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri 64108, USA
Pharmacotherapy 26:840-52. 2006..These potential effects can be managed with antiemetic prophylaxis and appropriate determination of the therapeutic rescue dose... - Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challengesJack J Chen
Department of Pharmacy Practice, Western University of Health Sciences, 309 East Second Street, Pomona, CA 91766, USA
Neurol Clin 22:S63-90. 2004 - A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type AJack J Chen
J Clin Psychiatry 66:267-8. 2005